Semaglutide(Yichang Humanwell)

Primary objective: To evaluate the similarity of the pharmacokinetic characteristics of a single subcutaneous injection of 0.25 mg of the investigational drug (T) semaglutide injection (provided by Yichang Renfu Pharmaceutical Co., Ltd., specification: 1.34 mg/ml, 1.5 ml) and 0.25 mg of the reference drug (R) semaglutide injection (produced by Novo Nordisk A/S, trade name: Novotec, specification: 1.34 mg/ mL, 1.5 ml) in healthy adult subjects under fasting conditions. Secondary objective: To evaluate the immunogenicity and safety of the investigational drug semaglutide injection and the reference drug (Novotec) in healthy adult subjects.